Liver News and Research

RSS

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb Company today reported results for the third quarter of 2010. Highlights in the quarter included: the presentation of new data on investigational compounds in the diabetes and cardiovascular disease franchises at major medical meetings; the completion of important regulatory milestones in the oncology, diabetes and immunoscience franchises; the acquisition of ZymoGenetics; and double-digit EPS growth. The company also confirmed guidance for 2010.

26 Oct 2010

Cancer researcher to receive 2010 AACR Award of excellence

John D. Groopman, Ph.D., has been selected to receive the 2010 American Association for Cancer Research-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research

26 Oct 2010

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called OPTIMIZE that will evaluate twice-daily (BID) dosing of a telaprevir-based combination regimen in people chronically infected with genotype 1 hepatitis C virus (HCV) who have not been treated previously. This is the first Phase 3 study to evaluate twice-daily dosing of a protease inhibitor for the treatment of hepatitis C. OPTIMIZE will not include a control arm of pegylated-interferon and ribavirin alone.

26 Oct 2010

Daily dose of whole body vibration reduces bone density loss

A daily dose of whole body vibration may help reduce the usual bone density loss that occurs with age, Medical College of Georgia researchers report.

25 Oct 2010

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Immune Network Ltd. advises that a clinical trial of V5 Immunitor oral vaccine was published earlier this month demonstrating an unexpected powerful effect against tuberculosis, including multi-drug-resistant tuberculosis (MDR-TB) and tuberculosis that is complicated by co-infection with HIV and hepatitis C (HCV).

25 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides

Essentialis, Inc. announced today that the company has reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 efficacy study required for product registration for its product candidate, Diazoxide Choline Controlled Release Tablet (DCCR), for the treatment of patients with very high triglycerides.

25 Oct 2010

New gene therapy product reduces plasma cholesterol levels

Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the development of gene based therapies, today announced that its gene therapy product incorporating siRNA sequences into microRNA scaffolds to silence Apolipoprotein B100 (AAV-miApoB) was able to significantly lower plasma cholesterol levels in vivo over a period of 18 weeks. These preliminary results suggest that this approach could lead to a treatment for high cholesterol in humans

25 Oct 2010

Targeting c-Met protein may be effective for patients with metastatic liver cancer

A more personalized treatment for people with a type of metastatic liver cancer hepatocellular carcinoma may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers.

25 Oct 2010

Childhood cancer survivors at increased risk of gastrointestinal problems

People treated for cancer when they were children have a higher-than-average risk of gastrointestinal problems - some mild, some quite severe - in the years following treatment, according to a study to be presented at the 42nd Congress of the International Society of Paediatric Oncology (SIOP) in Boston on Sunday, Oct. 24.

25 Oct 2010

Maven Semantic updates Antiviral research database

Maven Semantic announces updates to their Antiviral research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

25 Oct 2010

Scientists find two proteins that regulates water retention in salt-sensitive hypertension

Research conducted by scientists at LSU Health Sciences Center New Orleans has found that two proteins in the brain act as valves to turn the hormone that regulates water retention in the body on and off. Their findings may lead to advances in treatment for diseases like high blood pressure, congestive heart failure, and cirrhosis of the liver. The research is published in the November 1, 2010 issue of Endocrinology.

25 Oct 2010

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

UCSF scientists have received two grants from the California Institutefor Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure. The goal of the grants is for researchers to make significant strides toward the development of potential therapies within the next three years.

25 Oct 2010

Intestinal microbiota can increase broccoli’s cancer-preventive power: Research

A University of Illinois study has shown for the first time that sulforaphane, the powerful cancer-fighting agent in broccoli, can be released from its parent compound by bacteria in the lower gut and absorbed into the body.

22 Oct 2010

Medivir reports consolidated net sales of SEK 54.7M

Medivir AB , a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its interim report today for the period covering 1 January - 30 September and a business update for the third quarter 2010.

22 Oct 2010

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of biliary strictures, including biliary stone disease, benign biliary strictures, and suspected and confirmed malignancies in the biliary system. The product is now available in Europe and other international markets; the Company plans to launch it in the U.S. this quarter.

21 Oct 2010

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

Research identifies key regulators that control transmission of malaria parasite

Scientists at The University of Nottingham and the Wellcome Trust Sanger Institute near Cambridge have pin-pointed the 72 molecular switches that control the three key stages in the life cycle of the malaria parasite and have discovered that over a third of these switches can be disrupted in some way.

21 Oct 2010

Matrix-Bio's VeraMarker-BCR blood test predicts breast cancer recurrence 13 months before clinical diagnosis

Connie Krabbe understands the fear and foreboding breast cancer survivors feel when visiting their physicians for post-treatment check-ups. Two of her four sisters died of metastatic cancer related to breast cancer, enduring bone, brain, and ovarian cancer before succumbing to the disease in their early 50s.

21 Oct 2010

Researchers identify common link among malignant tumor types in all grades of cancer

Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth.

21 Oct 2010

Liver News and Research

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Cancer researcher to receive 2010 AACR Award of excellence

Vertex initiates OPTIMIZE Phase 3b study in patients infected with genotype 1 HCV

Daily dose of whole body vibration reduces bone density loss

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Essentialis, FDA enter agreement on SPA for DCCR Phase 3 efficacy study in patients with high triglycerides

New gene therapy product reduces plasma cholesterol levels

Targeting c-Met protein may be effective for patients with metastatic liver cancer

Childhood cancer survivors at increased risk of gastrointestinal problems

Maven Semantic updates Antiviral research database

Scientists find two proteins that regulates water retention in salt-sensitive hypertension

UCSF scientists receive grants to refine embryonic stem cell-based strategies for neurological diseases

Intestinal microbiota can increase broccoli’s cancer-preventive power: Research

Medivir reports consolidated net sales of SEK 54.7M

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Research identifies key regulators that control transmission of malaria parasite

Matrix-Bio's VeraMarker-BCR blood test predicts breast cancer recurrence 13 months before clinical diagnosis

Researchers identify common link among malignant tumor types in all grades of cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News